Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Net Cash Flow (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Net Cash Flow for 6 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 56.95% year-over-year to $19.4 million, compared with a TTM value of $39.3 million through Dec 2025, up 866.07%, and an annual FY2025 reading of $39.3 million, up 866.07% over the prior year.
  • Net Cash Flow was $19.4 million for Q4 2025 at Xeris Biopharma Holdings, down from $32.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $42.2 million in Q4 2022 and bottomed at -$71.0 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $3.9 million, with a median of $409000.0 recorded in 2023.
  • The sharpest move saw Net Cash Flow plummeted 294.47% in 2023, then surged 5751.85% in 2024.
  • Year by year, Net Cash Flow stood at $7.8 million in 2021, then surged by 442.41% to $42.2 million in 2022, then plummeted by 49.99% to $21.1 million in 2023, then plummeted by 41.3% to $12.4 million in 2024, then surged by 56.95% to $19.4 million in 2025.
  • Business Quant data shows Net Cash Flow for XERS at $19.4 million in Q4 2025, $32.2 million in Q3 2025, and $845000.0 in Q2 2025.